338 related articles for article (PubMed ID: 32374053)
21. Women's Health Update: Growing Role of PET for Patients with Breast Cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract][Full Text] [Related]
22. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.
Boers J; Venema CM; de Vries EFJ; Glaudemans AWJM; Kwee TC; Schuuring E; Martens JWM; Elias SG; Hospers GAP; Schröder CP
Eur J Cancer; 2020 Feb; 126():11-20. PubMed ID: 31891878
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of estrogen expression of breast cancer using
Seenu V; Sharma A; Kumar R; Suhani S; Prashanth A; Mathur S; Parshad R
World J Nucl Med; 2020; 19(3):233-239. PubMed ID: 33354178
[TBL] [Abstract][Full Text] [Related]
24. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA
J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268
[TBL] [Abstract][Full Text] [Related]
25. [18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant.
Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
[TBL] [Abstract][Full Text] [Related]
26. Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.
Venema CM; Apollonio G; Hospers GA; Schröder CP; Dierckx RA; de Vries EF; Glaudemans AW
Clin Nucl Med; 2016 Nov; 41(11):844-851. PubMed ID: 27607175
[TBL] [Abstract][Full Text] [Related]
27. The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.
Koleva-Kolarova RG; Greuter MJ; van Kruchten M; Vermeulen KM; Feenstra T; Buskens E; Glaudemans AW; de Vries EF; de Vries EG; Hospers GA; de Bock GH
Br J Cancer; 2015 May; 112(10):1617-25. PubMed ID: 25880006
[TBL] [Abstract][Full Text] [Related]
28. The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
Yang Z; Sun Y; Xu X; Zhang Y; Zhang J; Xue J; Wang M; Yuan H; Hu S; Shi W; Zhu B; Zhang Y
Clin Nucl Med; 2017 Jun; 42(6):421-427. PubMed ID: 28221191
[TBL] [Abstract][Full Text] [Related]
29. In vivo imaging of brain estrogen receptors in rats: a 16α-18F-fluoro-17β-estradiol PET study.
Khayum MA; de Vries EF; Glaudemans AW; Dierckx RA; Doorduin J
J Nucl Med; 2014 Mar; 55(3):481-7. PubMed ID: 24481026
[TBL] [Abstract][Full Text] [Related]
30. Analyzing the Estrogen Receptor Status of Liver Metastases with [
Boers J; Loudini N; de Haas RJ; Willemsen ATM; van der Vegt B; de Vries EGE; Hospers GAP; Schröder CP; Glaudemans AWJM; de Vries EFJ
Diagnostics (Basel); 2021 Oct; 11(11):. PubMed ID: 34829366
[TBL] [Abstract][Full Text] [Related]
31. Biodistribution of
Iqbal R; Yaqub M; Oprea-Lager DE; Liu Y; Luik AM; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
J Nucl Med; 2022 May; 63(5):694-699. PubMed ID: 34446451
[TBL] [Abstract][Full Text] [Related]
32. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
[TBL] [Abstract][Full Text] [Related]
33.
Nienhuis HH; van Kruchten M; Elias SG; Glaudemans AWJM; de Vries EFJ; Bongaerts AHH; Schröder CP; de Vries EGE; Hospers GAP
J Nucl Med; 2018 Aug; 59(8):1212-1218. PubMed ID: 29602822
[TBL] [Abstract][Full Text] [Related]
34. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
35. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of tumour heterogeneity by
Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
[TBL] [Abstract][Full Text] [Related]
37.
Grabher BJ
J Nucl Med Technol; 2023 Sep; 51(3):188-193. PubMed ID: 37433673
[TBL] [Abstract][Full Text] [Related]
38. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
[TBL] [Abstract][Full Text] [Related]
39. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
Goodman K; Abel MK; Lawhn-Heath C; Molina-Vega J; Jones EF; Mukhtar RA
Surg Oncol Clin N Am; 2022 Oct; 31(4):569-579. PubMed ID: 36243494
[No Abstract] [Full Text] [Related]
40. PET imaging of oestrogen receptors in patients with breast cancer.
van Kruchten M; de Vries EGE; Brown M; de Vries EFJ; Glaudemans AWJM; Dierckx RAJO; Schröder CP; Hospers GAP
Lancet Oncol; 2013 Oct; 14(11):e465-e475. PubMed ID: 24079874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]